REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

iBio acquires Fabry Disease Orphan Drug Designation and Development Program

23-02-2011. iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A (“α-Gal A”) and related property rights from an affiliate of Kentucky Bioprocessing LLC (“KBP”) and has initiated a program, based on its iBioLaunch™ platform, to develop an improved version of the enzyme for therapy of Fabry disease. iBio will work with its regular research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology, for product development, and with KBP for manufacture of clinical and commercial quantities of the new product for iBio or its licensees.
This Fabry disease therapeutic program will be part of iBio’s broader program to bring forward approximately ten more candidate proteins for commercialization as “biosimilar” or “biobetter” therapeutic products. iBio intends to advance these candidates to a point sufficient to demonstrate the advantages of making them using the iBioLaunch platform technology and then license them to industry partners. iBio already has demonstrated the applicability of its platform technology to most therapeutic protein classes, ranging from cytokines and growth factors to enzymes and antibodies.
Under its current program, iBio is selecting commercial targets that exemplify advantages of the iBioLaunch technology and meet apparent market needs. Selection of the Fabry disease candidate was influenced by: the current worldwide shortage of α-Gal A for enzyme replacement therapy for Fabry disease; the likelihood that the disease is significantly under-diagnosed; the opportunity to acquire Orphan Drug Designation for plant-produced α-Gal A (which can provide significant market protection and tax advantages); and iBio’s belief this will further demonstrate some of the advantages of our technology such as scalability for Orphan Drug applications, more rapid product development, and improved efficacy compared to other systems.  “We believe the unusual scalability, speed and efficiency of iBio’s plant-based protein expression platform technology can make important contributions to rapid development and availability of therapies against orphan diseases such as Fabry Disease,” said Robert Erwin, President of iBio.
Current estimates indicate a patient population affected by Fabry Disease of approximately 8,000 to 10,000. Current therapies are estimated to cost more than $200,000 per patient year. Symptoms usually begin in childhood. Unless continuously treated, Fabry Disease results in many severe health problems such as kidney failure, heart damage and cerebrovascular problems.

 

__________________

Disclaimer: You agree that  B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on   B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by  B2Bioworld.

 

___________


Note by B2Bioworld Editor: 


The affiliate is Alpha Gal LLC spun-off by Kentucky Bioprocessing. This company resp. Alpha Gal LLC acquired IP assets from Large Scale Biology Corporation which went bankrupt in 2006. Its plant-produced human A-Glactosidase A received orphan drug status in January 2003. To date tthe drug is not yet FDA approved.

 

A service for free to readers of B2Bioworld - Get out more of PR


“We have biosimilars coming …”

How Merck Serono is Facing Challenges in Manufacturing and Process Development

Jonathan BarnsleyJune 2010. With more challenges ahead to face the lower cost environment of medical health care, at issue is process development to ensure peak process performance, selecting alternative technology platforms and adapting them to industrial scale. In an interview with B2Bioworld Jonathan Barnsley, Senior Vice President, Biotech Manufacturing & Process Development Merck Serono, describes opportunities and threats.



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview, 3 pages

M.Mehtali, VIVALIS: Stem Cells and Vaccines

Dr. Majid Mehtali (C) Wolf G Kroner 2009November 2009. Dr. Majid Mehtali, CSO of Vivalis gives a personal perspective on demand for stem cell application, outlines Vivalis’ expansion strategies and answers questions on financing and cash burn. Includes overview on licencing agrrements since 2002.



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

enquiry/licences info,3 pages

Top 10 Tags

All Tags (2094)